FocalTherics (NASDAQ:FOCL) Director Joshua Levine Purchases 10,000 Shares of Stock

FocalTherics (NASDAQ:FOCL) Director Joshua Levine purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the transaction, the director owned 45,000 shares of the company’s stock, valued at $213,750. This trade represents a 28.57% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

FocalTherics Stock Performance

FOCL opened at $4.36 on Tuesday. The firm has a fifty day moving average price of $5.38. The stock has a market capitalization of $163.41 million, a PE ratio of -4.23 and a beta of -0.04. FocalTherics has a fifty-two week low of $1.30 and a fifty-two week high of $6.40. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79.

FocalTherics (NASDAQ:FOCL) last posted its earnings results on Friday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%.The firm had revenue of $13.20 million for the quarter. On average, equities research analysts forecast that FocalTherics will post -0.78 earnings per share for the current year.

Key Headlines Impacting FocalTherics

Here are the key news stories impacting FocalTherics this week:

• Positive Sentiment: Company insiders collectively purchased 116,000 shares at $4.75 per share, representing approximately $551,000 of open-market buying. The purchases included CEO Ryan Rhodes, CFO Kenneth S. Mobeck, General Counsel Sanket Shah, SVP Steven Annen, and Directors Lance Willsey, Joshua Levine, Fran Schulz, and David R. Horn. The coordinated buying may suggest that management and directors view the recent weakness as an attractive entry point. FocalTherics insider transaction filing
• Positive Sentiment: Director Lance Willsey made the largest purchase, acquiring 50,000 shares for $237,500. CEO Ryan Rhodes also bought 21,000 shares for $99,750, while several other executives and directors increased their holdings by between 2.83% and 196.08%. FocalTherics director transaction filing
• Negative Sentiment: FocalTherics recently reported quarterly earnings of a $0.39-per-share loss, missing the consensus estimate for a $0.20 loss by $0.19. Revenue was $13.20 million, while the company posted a negative net margin of 56.26% and negative return on equity of 175.45%. Analysts expect a full-year loss of approximately $0.78 per share, which remains a key risk for the stock.

Institutional Investors Weigh In On FocalTherics

Several institutional investors have recently bought and sold shares of the company. SmartHarvest Portfolios LLC purchased a new stake in FocalTherics during the 1st quarter worth approximately $38,000. Lido Advisors LLC purchased a new position in shares of FocalTherics in the first quarter valued at approximately $40,000. Kovack Advisors Inc. acquired a new stake in shares of FocalTherics in the fourth quarter worth approximately $53,000. Leonteq Securities AG acquired a new stake in shares of FocalTherics in the fourth quarter worth approximately $313,000. Finally, Flax Pond Capital LLC purchased a new stake in shares of FocalTherics during the fourth quarter worth approximately $2,623,000. 62.74% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on FOCL shares. Mizuho set a $15.00 price objective on FocalTherics and gave the company an “outperform” rating in a report on Friday, July 17th. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 target price on shares of FocalTherics in a research note on Friday. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of FocalTherics in a research report on Tuesday, June 2nd. Finally, Wall Street Zen lowered shares of FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.75.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.